Ionis’ Tryngolza Hits ‘Best-Case Scenario’ in Late-Stage Triglyceride Study

Aside from lowering triglyceride levels, Ionis’ olezarsen reduced acute pancreatitis events, an outcome that BMO Capital Markets said could help the asset deliver a “significant first-in-class commercial launch.”